| Number of participants with four‐fold rise in antibody titre 4 weeks after last immunisation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Influenza strain | Group 1. First dose n% | Total N of participants | Group 1. Sec dose n% | Total N of participants | Group 2. First dose n% | Total N of participants | Group 2. Sec dose n% | Total N of participants | P‐value |
| Hsieh 2002a | A/NC/20/99 | 6 (42.9%) | 14 | 6 (42.9%) | 14 | 5 (45,5% | 11 | 5 (45.5%) | 11 | 0.84 = NS comparing Group 1 Second dose to Group 2 Second dose |
| Hsieh 2002a | A/Pan/2007/99 | 4 (28.6%) | 14 | 5 (35.7%) | 14 | 0 (0%) | 11 | 1 (9.1%) | 11 | 0.12 = NS comparing Group 1 Second dose to Group 2 Second dose |
| Hsieh 2002a | B/Yam/166/98 | 7 (50%) | 14 | 8 (57.1%) | 14 | 8 (72.7%) | 11 | 7 (63.6%) | 11 | 0.84 = NS comparing Group 1 Second dose to Group 2 Second dose |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.